Determinants of Abl kinase stability and drug binding thermodynamics: Role of regulatory domains and phosphorylation
Abstract Activity dysregulation of Abl kinase is the primary cause for chronic myeloid leukemia (CML). Despite extensive characterization, the thermodynamic basis of Abl stability and inhibitor recognition remains incompletely understood. To characterize the cooperative folding organization of Abl and the communication between its structural units, we comprehensively characterized three Abl constructs: the isolated catalytic domain (Abl CD ), the three‐domain regulatory construct (Abl SH3SH2CD ), and its phosphorylated form ( PO4 Abl SH3SH2CD ), using high‐resolution calorimetric techniques. DSC revealed that the catalytic domain behaves as a single cooperative unfolding unit, with the SH3–SH2 module in Abl SH3SH2CD exerting a modest stabilizing effect. The catalytic domain decoupled into two transitions in PO4 Abl SH3SH2CD , an observation rationalized by the disruption of the interlobe structural bridge formed by the A‐loop in the unphosphorylated forms. Imatinib and dasatinib had opposite effects on this decoupling, providing calorimetric evidence for the distinct intradomain reorganizations induced by each inhibitor type. ITC showed that both inhibitors bind with distinct thermodynamic signatures, with a modest effect of the regulatory domains on inhibitor recognition. Imatinib binding involved net proton uptake, consistent with Asp381 protonation required for the DFG‐out transition, while dasatinib showed no proton linkage. Phosphorylation‐induced reduction in imatinib affinity was driven by a large loss of favorable enthalpy reflecting the energetic cost of displacing the ordered A‐loop, while dasatinib affinity remained largely unaffected. These results provide a thermodynamic rationale for the superior potency of dasatinib against activated Abl in CML cells, revealing mechanistic features of kinase regulation not accessible from structural data alone.
Authors
- Enrique García‐Hernández (ORCID: https://orcid.org/0000-0003-4561-4973)
- Axel Luviano (ORCID: https://orcid.org/0000-0003-3985-8349)
- Alan Juárez-Barragán
- Ileana Tobías-Juárez
- J. Alberto Escobar‐Cázares (ORCID: https://orcid.org/0009-0002-8480-0912)
- Miguel A. Medina‐Gómez (ORCID: https://orcid.org/0009-0008-2466-5329)
Institutions
- Universidad Autónoma de la Ciudad de México (MX)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- Protein Science
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1002/pro.70791
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00